Paul has over 30 years of experience industrializing biologics for numerous biotechnology companies. Prior to joining Vaxcyte, Paul was VP of Process Sciences & Manufacturing at Igenica Biotherapeutics, where he initiated the company’s development activities and built its supply chain network for GMP manufacturing of its antibody drug conjugates. Prior to that, Paul was Senior Director of Process Development at OncoMed Pharmaceuticals, where he contributed to multiple IND filings for the company’s antibody-based oncology therapies. He also held various process, engineering, scale-up, and manufacturing positions at Protein Design Labs, Scios, and Genentech. Through the years, Paul has contributed to numerous approved biologics, including Genentech’s Activase® and Pulmozyme®. He also contributed significantly to the development of the patented high-yield process that formed the basis for production of Abbvie and Biogen’s ZinbrytaTM, a humanized antibody approved for the treatment of Multiple Sclerosis. Paul earned an MBA at Santa Clara University and a BS in Genetics from the University of California, Davis.

• 

  Senior Vice President, Development and Manufacturing in Vaxcyte

  Vaccine Innovation. Beyond Convention.